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The discovery of new chemical entities endowed with potent and selective acetylcholinesterase (AChE)
and/or butyrylcholinesterase (BChE) inhibitory activity is still a relevant subject for Alzheimer's disease
therapy. Therefore, a small library of benzoic based amide nitrones (compounds 24 to 42) was synthe-
sized and screened toward cholinesterase enzymes. SAR studies showed that the tert-butyl moiety is the
most favourable nitrone pattern. In general, tert-butyl derivatives effectively inhibited AChE, being
compound 33 the most potent (IC50¼ 8.3± 0.3 mM; Ki 5.2 mM). The data pointed to a non-competitive
inhibition mechanism of action, which was also observed for the standard donepezil. None of com-
pounds showed BChE inhibitory activity. Molecular modelling studies provided insights into the enzyme-
inhibitor interactions and rationalised the experimental data, confirming that the binding mode of
nitrones 33 and 38 towards AChE has the most favourable binding free energy.
The tert-butylnitrones 33 and 38 were not cytotoxic on different cell lines (SH-SY5Y and HepG2).
Moreover, compound 33 was able to prevent t-BHP-induced oxidative stress in SH-SY5Y differentiated
cells.
Due to its AChE selectivity and promising cytoprotective properties, as well as its appropriate drug-like
profile pointing toward blood-brain barrier permeability, compound 33 is proposed as a valid lead for a
further optimization step.
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Fig. 2. General structure of novel ChEIs amide nitrones based on benzoic acid (BA).
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Alzheimer's disease (AD) is the most common type of dementia
[1], accounting for up to 70% of cases worldwide [2,3], and being
characterized as a multifactorial disease [4e7]. AD is associated
with a decrease of cholinergic activity and is also related with
increased oxidative stress (OS) [8,9]. Cholinesterases (ChE), a family
of enzymes that mainly catalyse the hydrolysis of the neurotrans-
mitter acetylcholine (ACh), are involved in the restoration of the
cholinergic pathway at the end of the nerve transmission [9,10].
There are two main types of ChEs identified so far, namely acetyl-
cholinesterase (AChE) and butyrylcholinesterase (BChE): AChE hy-
drolyses ACh and BChE hydrolyses butyrylcholine (BCh) [10,11].
While AChE prevails in the healthy brain, BChE has a negligible
starring role in the regulation of synaptic ACh levels [9,12].
Accordingly, the use of selective AChE inhibitors (AChEI) is an
important therapeutic approach for AD. Cholinesterase inhibitors
(ChEIs) have shown several benefits including reduced degradation
of synaptic ACh, improvement of brain ACh levels in a dose-
dependent manner resulting in an enhanced cholinergic trans-
mission in patients with AD and other dementias. However, the
drugs currently approved by Food and Drug Administration (FDA)
[8,13,14], namely donepezil and galantamine (selective and
reversible AChEIs) and rivastigmine (a dual cholinesterase inhibitor,
which can inhibit both AChE and BChE) are unable to modify dis-
ease progression.
Oxidative stress-related events are also relevant for AD pro-
gression. For instance, OS and mitochondrial damage have been
associated with AD associated events [4], as the OS redox changes in
specific cellular components cause a more oxidized state, bringing
about to an augmented production of reactive oxygen species (ROS)
and/or less effective intrinsic antioxidant activity [15].
Over the past decade, there have been substantial efforts to
design multi-target drugs (MTDs) as a therapeutic solution for AD,
an approach that is moved by the increase knowledge that AD is a
complex and multifactorial disease affecting many interlinked
pathological pathways. In this context, the development of new
chemical entities able to prevent and/or minimize OS-related
events with remarkable capacities to inhibit ChE activity is still a
relevant issue.
Nitrones, a class of compounds known as spin traps, were
described as having the ability to stabilize or trap free radicals and
reduce the damage associated with unbalanced production of
radical reactive species [16,17]. These compounds comprise the
general structure R1-CH]NO-R2 (Fig. 1a) and the underlying
mechanism behind their free radical trapping action is related to
their ability to interact with highly reactive oxygen- and carbon-
centred radicals (X) yielding nitroxide products (Fig. 1b), which
are then stabilized by resonance [18,19].
Following a MTD strategy in the present work we report the
design and synthesis of new hybrid nitrones (benzoic based amide
nitrones) as potential ChEIs endowed with neuroprotective prop-
erties. Structural modifications were performed on the aromatic
pattern, spacer length and type of nitrone covalently bound to the
carbon flexible aliphatic chain (Fig. 2). All derivatives wereFig. 1. Free radical trapping mechanism of nitrones.evaluated for ChEs inhibition, kinetics andmechanism of enzymatic
inhibition, cytotoxicity, antioxidant profile in cell-based systems
and drug-like properties. In addition, in order to rationalize our
results, docking experiments were performed using models built
based on the crystal structures of human AChE and BChE.
2. Results and discussion
2.1. Chemistry
The synthesis of novel hybrid nitrones structurally based on
benzoic acid was performed following the synthetic strategy
depicted in Scheme 1. The compounds were obtained in three
synthetic steps using benzoic acid (1), 3-methoxybenzoic acid (2),
4-methoxybenzoic acid (3), 3,4-dimethoxybenzoic acid (4) and
3,4,5-trimethoxybenzoic acid (5) as starting materials. The first
synthetic step consisted of an amidation reaction of benzoic acids
1e5 using dissimilar coupling agents, and different length of the
linker spacers. Therefore, ethyl chloroformate (step a) was used for
the introduction of the 6-aminohexan-1-ol spacer, yielding com-
pounds 6e9 and 12. Alternatively, phosphorus oxychloride (step b)
was used with the 8-aminooctan-1-ol and 10-aminodecan-1-ol
spacers, yielding derivatives 10e11 and 13e14. The following re-
action (step c) was the oxidation of the alcohol group of compounds
6e14 to the corresponding aldehydes 15e23 with pyridinium
chlorochromate. Nitrones 24e42 were then obtained via a
microwave-assisted reaction (step d) using three different hy-
droxylamines (N-tert-butylhydroxylamine hydrochloride, N-ben-
zylhydroxylamine hydrochloride and N-cyclohexylhydroxylamine
hydrochloride). Following this strategy, we successfully synthe-
sized a series of derivatives with different aromatic substitution
patterns, aliphatic chain length spacers and nitrone moieties.
2.2. Assessment of acetyl and butyrylcholinesterase inhibition
AChE and BChE inhibitory activity of nitrones 24e42 was eval-
uated following the Ellman's method [20,21], with AChE from
Electrophorus electricus (electric eel, eelAChE) and BChE from
equine serum (eqBChE). Acetylthiocholine iodide (ATCI) or butyr-
ylthiocholine iodide (BTCI) were used as substrates for AChE or
BChE, respectively, releasing thiocholine and acetate or butyrate.
Then, thiocholine reacts with 5,50-dithiobis-(2-nitrobenzoate)
(DTNB) ion to produce 5-thio-2-nitrobenzoate (TNB2) anion,
which was determined by UV/Vis spectroscopy [20,21], enabling
the screening for ChE inhibition after incubation with the test
compounds. Donepezil used as standard ChE inhibitor [10] showed
a higher potency for AChE than BChE (IC50¼ 25± 1 nM and
2.2± 0.2 mM, respectively). The results of the inhibitory potency
(IC50 values) of compounds under study and standard inhibitor
(donepezil) are shown in Table 1.
Scheme 1. Synthetic strategy followed to obtain nitrone derivatives 24e42 from benzoic acids 1e5. Reagents and conditions: a. Et3N, ClCOOC2H5, NH2(CH2)5CH2OH, r.t., 10 h; b.
POCl3, NH2(CH2)7CH2OH or NH2(CH2)9CH2OH, DIPEA, 1e2 h; c. PCC, CH2Cl2, 2 h; d. (CH3)3CNHOH$HCl, C6H5CH2NHOH$HCl or C6H11NHOH$HCl, NaHCO3, MW, 90 C, 10e15min.
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and selective AChEIs. The aromatic ring substituents as well as the
spacer length and the nitrone moiety had a significant influence on
AChE inhibitory activity. Firstly, the type of substituent of the
nitrone group (24e42) markedly influenced the activity, as only the
derivatives bearing a tert-butyl group (27, 30, 33, 36e38, 41 and 42)
were active toward AChE (IC50¼ 8.3e27.2 mM). Curiously, the
introduction of benzyl and cyclohexyl nitrone moieties did not lead
to the same outcome.
The aromatic ring substituents also had a significant effect on
AChE inhibition. Indeed, while benzoic acid derivatives (24e26)
lacked inhibitory activity toward AChE, the introduction of
methoxy groups led to an enhancement of the inhibitory effect.
Although the introduction of m- or p-OCH3 substituents (com-
pounds 27 and 30) led to similar inhibitory potencies
(IC50¼ 27.2± 2.9 and 26.1± 2.7 mM, respectively), a significant
improvement was observed for the 3,4,5-trissubstituted derivative
38 (IC50¼17.2± 1.3 mM) and, in particular, for the 3,4-dimethoxy
derivative 33 (IC50¼ 8.3± 0.3 mM).
Then, we studied the effect of the length of the alkyl linker for
the derivatives with optimal aromatic patterns (3,4-dimethoxy and
3,4,5-trimethoxy) and nitrone moiety (tert-butylnitrone). Accord-
ingly, the spacer was replaced by an eight- and ten-carbon chain. It
was observed that the increase of the spacer for the 3,4-OCH3 de-
rivatives (compounds 36 and 37) did not progress the inhibitory
potency but for 3,4,5-OCH3 derivatives (compounds 41 and 42)
although a slight improvement of inhibitory activity was noticed,
reaching a mild 1.5-fold increase for nitrone 42
(IC50¼11.8± 0.8 mM), which had a ten-carbon spacer.
As none of the precursors (1e5) were active against AChE at the
highest concentration tested (50 mM) it can be concluded that the
presence of a positively charged terminal nitrogen (tert-butylnitrone) and an alkyl spacer is required for activity. Moreover,
nitrones are selective for AChE as none of the compounds (nitrones
and precursors) showed inhibitory activity for BChE at the highest
concentration tested (50 mM).2.3. Assessment of drug-like properties
The drug-like properties were determined for all the nitrone
derivatives (24e42), donepezil and precursors 1e5 (see SI). The
calculated parameters encompassed: molecular weight (MW),
partition coefficient (clog P), topological polar surface area (tPSA in
Å2), number of hydrogen acceptors (HBA), number of hydrogen
donors (HBD), number of rotatable bonds (nrotb) and blood
(plasma)-brain partitioning (logBB) (Table 2).
For nitrones with tert-butyl moiety (27, 30, 33, 36e38, 41 and
42, Table 2), we observed that the values of HBA and HBD were in
agreement with the drug-likeness requirements of the Linpinski's
“Rule of 5” (with HBA < 10 and HBD < 5) [22]. In general, all
compounds exhibited a clogP value lower than 5, with the clogP
values ranging from 2.59 to 5.05, which is within the optimal range
for orally administered and central nervous system (CNS) drugs
[22,23]. However, comparing with CNSþ drug parameters, com-
pounds 38, 41 and 42 displayed a value of HBA¼ 7, which is out of
the proposed range.
The prediction of blood-brain barrier (BBB) permeability,
determined by the logBB (the ratio of the steady-state concentra-
tions of the drug in the brain and in the blood) was also assessed.
Compounds with logBB below 1 are poorly distributed to the
brain and are improbable to operate as effective CNS drugs [24]. All
nitrones depicted on Table 2 displayed logBB>1, pointing to-
wards potential BBB permeability.
Table 1
AChE and BChE inhibitory activity (IC50) of nitrone derivatives 24e42 and donepezil.
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Table 1 (continued )






0.025± 0.001 2.2± 0.2
a Inactive at 50 mM (highest concentration tested).
Table 2
Drug-like properties of nitrones derivatives with tert-butyl moiety (27, 30, 33, 36e38, 41 and 42).
Compound MWa clog Pa tPSA (Å2)a HBAa HBDa nrotba log BBa
27 320.4 2.99 67.08 5 1 10 0.232
30 320.4 2.99 67.08 5 1 10 0.232
33 350.5 2.80 76.31 6 1 11 0.086
36 378.5 4.15 76.31 6 1 13 0.109
37 406.6 5.05 76.31 6 1 15 0.115
38 380.5 2.59 85.54 7 1 12 0.004
41 408.5 3.94 85.54 7 1 14 0.028
42 436.6 4.85 85.54 7 1 16 0.035
CNSþ drugs [7,25-28] < 450 < 5 < 60-70 < 7 < 3 < 8  1
MW:molecular weight; clog P: logarithm of the octanol-water partition coefficient; tPSA: topological polar surface area; HBA: number of hydrogen acceptors; HBD: number of
hydrogen donors; nrotb: number of rotatable bonds; log BB: logarithm of the ratio of the concentration of a drug in the brain and in the blood.
a Properties calculated using StarDrop software.
Table 3
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To study the influence of the nitrone substituents on hChEs
molecular recognition, compounds 27e35 and 38e40 were sub-
mitted to molecular docking simulations and the resulting theo-
retical complexes were scored using the Molecular Mechanics/
Generalized Born Surface Area (MM-GBSA) binding free energy
estimation [29]. Differently fromwhich was observed for hBChE, all
evaluated compounds in hAChE assumed an extended conforma-
tion. The reason of this different behaviour could be related to the
known structural differences between the two isoenzymes active
sites [30,31] (Fig. S1). Indeed, overlapping hBChE poses into the
hAChE pocket, it was observed that the aromatic residues Phe295,
Phe297 and Tyr337 prevented the ligand folded conformation. In
fact, these amino acids, in hBChE, are replaced by Leu286, Val288
and Ala328, respectively, resulting in less steric hindrance.
Although the studied compounds were able to bind the active site
of both isoforms their binding free energies suggested for the tert-
butyl derivatives 27, 30, 33, 38 a hAChE preference over hBChE
(Table 3), with nitrones 33 and 38 as the most energetically
favourite hAChE ligands, which are in a qualitative agreement with
the experimental data.
In particular, into the hAChE active site compounds 33, 27, 30,
and 38 (Figs. 3, S2eS4, respectively) shared both the orientation of
the tert-butyl group towards the inner side of the gorge and
established hydrogen bond to Phe295 backbone by means of the
amide oxygen. Into the hAChE, stacking interactions with the
external Trp286 further stabilized 27, 33 and 38 complexes.
The corresponding benzyl derivatives 28, 31, 34 (Figs. S5eS7)equally interacted with Phe295 and Trp286 and maintained the
same orientation. On the contrary, 3,4,5-trimethoxy phenyl ring of
the derivative 39 was positioned near the internal Trp86. Never-
theless, this compound performed hydrogen bond to Phe295
backbone by the nitrone oxygen, and its benzyl ring was oriented
towards the Trp286 (Fig. S8). Thus, both the number and position of
themethoxy group(s) at the aromatic ring and the tert-butyl/benzyl
substituents seemed to have the same influence on the hAChE
interactions.
Regarding the cyclohexyl ring substituted derivatives 29, 32, 35
and 40 (Figs. S9eS12), it was observed that 29 and 35, conversely to
their tert-butyl analogues, respectively directed the 3-methoxy and
3,4-dimethoxy phenyl ring towards to the internal Trp86
Fig. 3. Best docking pose of compound 33 into hAChE active site displayed as light blue mesh. The most relevant interacting residues and the ligand are respectively depicted in light
blue and yellow tubes. Stacking interactions and hydrogen bonds are respectively represented in green and purple.
C. Oliveira et al. / European Journal of Medicinal Chemistry 174 (2019) 116e129 121establishing stacking interactions, while the hydrogen bond with
Phe295 was established by the nitro group oxygen, similarly to
compound 39. Contrariwise, the binding modes of 32 and 40 were
similar with those observed for 30 and 38.
Therefore, docking findings indicated that all studied com-
pounds were able to bind to hAChE active site mainly interacting
with Trp286 and Phe295, belonging to the peripheral anion site
(PAS) and to the acyl pocket, respectively, which play a key role in
ligand binding and specificity [32,33].
However, according to the biological data attained with the
nitrone group substituted by benzyl (28, 31, 34, 39) and cyclohexyl
moieties (29, 32, 35, 40) were endowedwith aworst hAChE binding
free energy compared to the corresponding tert-butyl analogous.
Analysing each MM-GBSA term contributing to the binding free
energy definition it was observed that the solvation free energy
(Generalized Born electrostatic solvation energy) mostly penalized
the benzyl and cyclohexyl derivatives (Table S2).
Focusing on the hBChE complexes, as previously reported, these
inhibitors showed a folded conformation not dependent from the
substituent at the phenyl and nitro moieties. Specifically, the tert-
butyl derivatives 27, 30 and 38 (Figs. S13eS15) respectively ori-
ented the 3-methoxy, 4-methoxy and 3,4,5-trimethoxyphenyl ring
towards the Phe329 performing stacking contacts, while the 3,4-
dimethoxyphenyl ring of 33 interacted to Tyr332 (Fig. S16).
Concerning the benzyl derivatives, the docking poses of 28
(Fig. S17) and 34 (Fig. S18) were quite similar to the 31 (Fig. S19) and
39 (Fig. S20) ones. In particular, 28 and 31 directed the methox-
yphenyl ring towards the Tyr332 and the benzyl one towards the
Trp231; in the docking geometries of 34 and 39 such moiety was
arranged in an opposite manner.
Similar configuration of 34 and 39 was observed for the cyclo-
hexyl derivatives 29, 35 and 40 (Figs. S21-S23). Instead, regarding
32 both the 4-methoxyphenyl and cyclohexyl ring were located
near to Tyr231 and no productive interactions were observed
(Fig. S24). Finally, 27, 30, 31, 39 and 40 poses highlighted steric
hindrance penalties with the residues of the catalytic triad, which
could disfavour the hBChE recognition. Any issue related with Pan
Assay INterference compoundS (PAINS) was found for thecompounds under study.
2.5. Assessment of enzyme-inhibition mechanism
To evaluate the inhibition mechanism of the most promising
AChEIs (compounds 33 and 38) kinetic experiments were per-
formed. For this purpose, the enzyme inhibition kinetics was
evaluated using different substrate concentrations (ATCI), in
absence or presence of compounds 33, 38 and donepezil at
different concentrations. The results are shown in Fig. 4. Graphical
analyses of the reciprocal Lineweaver-Burk plots were used to
determine Michaelis-Menten reaction kinetic parameters
(Michaelis constant, Km and maximum velocity, Vmax).
Concerning compound 33, it was found that the Vmax decreased
while Km appears to remain unchanged (Fig. 4A), displaying a series
of converging lines on the same point of the x-axis (1/[S]). The data
pointed to a non-competitive inhibition mechanism of action,
which was also observed for the standard donepezil (Fig. 4C), as
expected [34,35]. The Lineweaver-Burk plots obtained for com-
pound 38 (Fig. 4B) presented a series of converging lines displaying
a behaviour corresponding to a mixed inhibition, which is charac-
terized by the decrease of Vmax and Km. Actually, a mixed inhibitor
can hinder the binding of substrate and decrease the turnover
number of the enzyme [36].
From the Dixon plots, obtained from the replots of the slopes of
the Lineweaver-Burk plots vs. Inhibitor concentrations (Fig. 4, up-
per right corners), the AChE inhibition binding affinities, deter-
mined as inhibition constants (Ki), were calculated. Compounds 33
(Fig. 4A) and 38 (Fig. 4B) displayed Ki values of 5.2 and 10.4 mM,
respectively. The Ki values of compounds 33 (IC50¼ 8.3 mM) and 38
(IC50¼17.2 mM) correlated well with their experimental IC50, dis-
playing IC50 and Ki values slightly equal. Donepezil showed a
similar behaviour (Ki¼ 16.4 nM and IC50¼ 24.6 nM, Fig. 4C).
2.6. Assessment of cytotoxicity
The cytotoxic profile of the compounds 24e42 (see SI and Fig. 5)
was determined by measuring the cellular viability, in human
Fig. 4. Kinetic studies on the mechanism of AChE inhibition by (A) compounds 33 and (B) 38, and (C) donepezil. Details in reference [39].
Fig. 5. Cellular viability of human neurablastoma SH-SY5Y and human hepatocarcinoma HepG2 cells after a 24 h treatment with three different concentrations (1, 10 and 50 mM) of
nitrone compounds (A) 33 and (B) 38. Cellular viability was evaluated through variations in cell metabolic activity using two methods: MTT and resazurin reduction assays in
differentiated SH-SY5Y and HepG2 cells, respectively. Untreated cells were used as control. Results are expressed as mean % of untreated controls± SEM. (n¼ 4).
C. Oliveira et al. / European Journal of Medicinal Chemistry 174 (2019) 116e129122differentiated neuroblastoma (SH-SY5Y cell line) and hep-
atocarcinoma (HepG2) cells, after a 24 h incubation period at three
different concentrations (1, 10 and 50 mM). Both cell lines are often
used in the preclinical safety assessment of CNS drug candidates
[37]. Cellular viabilities were estimated through the capability of
living cells to metabolically reduce MTT and resazurin to formazan
and resorufin, respectively, providing an indirect measure ofmetabolic function [38]. The results obtained are shown in Fig. 5.
In general, the most promising compounds 33 (Fig. 5A) and 38
(Fig. 5B) with tert-butyl nitrone moiety did not exhibit a cytotox-
icity toward SH-SY5Y and HepG2 cells for all tested concentrations.
Interestingly, these compounds slightly increased cell viability
(106.8e122.1%) for all tested concentrations in differentiated SH-
SY5Y cells, an effect that was not observed in HepG2 cells.
C. Oliveira et al. / European Journal of Medicinal Chemistry 174 (2019) 116e129 123In brief, the data showed that the nitrone derivatives under
study did not display significant toxicity effects neither in human
SH-SY5Y nor HepG2 cells at concentrations inwhich they exhibited
AChE inhibitory activities, revealing a satisfactory safety window.2.7. Assessment of OS-induced cell death prevention
The antioxidant properties of the most promising nitrone
compounds (33 and 38) against OS-induced cell damage were
evaluated in SH-SY5Y differentiated cells, at 10, 50, 100 mM. TwoFig. 6. Antioxidant cytoprotective effects of tert-butyl nitrones, 33 and 38. (A) Schematic rep
activity of compounds (B) 33 and (C) 38, were evaluated in human neuroblastoma SH-SY
activity. The comparisons were performed by using one-way ANOVA between the con
means ± SEM of four independent experiments and the results are expressed as percentag
respective time point. Significance was accepted with * P < 0.05, **P < 0.01, ****P < 0.0001different strategies were used: a) the tested compounds were pre-
incubated for 24 h at non-cytotoxic concentrations, and then pro-
oxidant agents were added to the cell culture; and b) the pro-
oxidant agents were first added to the cell culture and then the
tested compounds were incubated for 24 h, at non-cytotoxic con-
centrations (Fig. 6A).
In the present study, classical pro-oxidant agents were used:
hydrogen peroxide (H2O2), tert-butyl hydroperoxide (t-BHP), the
mitochondrial inhibitors rotenone and antimycin A (ROT/AA), and
the anti-cancer agent doxorubicin (DOX). The selected oxidativeresentation of strategies used to evaluate nitrones' antioxidant properties. Antioxidant
5Y cells against H2O2-, t-BHP-, ROT/AA-, and DOX-induced decrease in cell metabolic
trol (oxidative stressors) vs. Nitrones under study when were incubated. Data are
e of control (control ¼ 100%), which represents the cells without any treatment in the
.
C. Oliveira et al. / European Journal of Medicinal Chemistry 174 (2019) 116e129124stressors induced oxidative events by different mechanisms: H2O2
is a product of enzymatic activity and dopamine oxidation and can
be converted into hydroxyl radicals via Fenton-like reactions [15];
t-BHP is an organic peroxide that causes lipid peroxidation, open-
ing of mitochondria nonspecific Ca2þ-dependent pore, and cell
death [39]; ROT/AA are inhibitors of the mitochondrial electron
transport chain, resulting in a burst of superoxide anion production
and induction of a ROS-dependent cell damage cascade events; and
DOX is a chemotherapeutic drug which generates a redox cycle at
different dehydrogenases, including mitochondrial complex I,
leading to superoxide anion production, and consequently to
mitochondrial dysfunction. Cells treated with H2O2 (1mM, Fig. 6B),
t-BHP (250 mM, Fig. 6B), ROT/AA (1 mM, Fig. 6B), and DOX (1 mM,
Fig. 6B) caused a significant reduction, of about 50.3± 1.1%,
44.3± 6.4%, 20.7± 2.1% and 32.9± 6.7%, respectively, in cell meta-
bolic activity when compared with nontreated cells.
In general, none of the promising AChEIs showed remarkable
antioxidant effects (Figs. 6B and C). However, compound 33 was
able to prevent the t-BHP-induced cell damage in a dose-
dependent manner (Fig. 6B), a property that can be enhanced af-
ter a subsequent optimization step.
3. Conclusions
The development of new benzoic based amide nitrones (com-
pounds 24e42), with different nitrone substituents (tert-butyl,
benzyl and cyclohexyl), was successfully achieved. The compounds
were screened toward cholinesterase enzymes and SAR studies
showed that the tert-butyl moiety is the most favourable nitrone
pattern. Only compounds with the tert-butyl moiety (27, 30, 33, 36,
38, 41 and 42) displayed significant AChE inhibitory activity.
Moreover, the presence and number of methoxy substituents, as
well as the spacer length, were found to be important contributors
for AChEI modulation potency. Compound 33, with two methoxy
functions and a six-carbon aliphatic chain, presented the best
inhibitory activity toward AChE (IC50¼ 8.3± 0.3 mM; Ki 5.2 mM). The
data pointed to a non-competitive inhibition mechanism of action,
which was also observed for the standard donepezil. None of
compounds showed BChE inhibitory activity.
Molecular modelling studies provided insights into enzyme-
inhibitor interactions and a rationale for the selectivity and po-
tency was observed, confirming that nitrones 33 and 38 resulted in
the most energetically favourable hAChE ligands.
The most promising tert-butylnitrones 33 and 38 slightly
increased the cell viability (106.8e122.1%) for all tested concen-
trations in differentiated SH-SY5Y cells and did not have a signifi-
cant effect on the cellular viability in HepG2 cells. Nitrone
derivatives 33 and 38 revealed a satisfactory safety window as they
did not display toxic effects in both cell lines. Furthermore, com-
pound 33 was able to prevent the t-BHP-induced cell damage in a
dose-dependent manner in SH-SY5Y differentiated cells, a property
that can be enhanced after a subsequent optimization step.
Due to its AChE selectivity and promising cytoprotection prop-
erties, as well as its appropriate drug-like properties, pointing to-
wards BBB permeability compound 33 is proposed as a valid lead
for further optimization step.
4. Experimental section
4.1. Chemistry
4.1.1. Synthesis of benzoic acid-derived nitrones
4.1.1.1. General procedures to obtain benzamide derivatives (6e14).
A1) The appropriate benzoic acid (benzoic acid (1), 3-
methoxybenzoic acid (2), 4-methoxybenzoic acid (3), 3,4-dimethoxybenzoic acid (4) or 3,4,5-trimethoxybenzoic acid (5),
1mmol), was dissolved in dichloromethane (40mL) and triethyl-
amine (2mmol) was added. Then, ethyl chloroformate (2mmol)
was added dropwise to the stirred solution kept in an ice bath. After
stirring 2 h at room temperature, the mixture was cooled again and
the 6-aminohexan-1-ol (2mmol) was added. The purification
conditions are described in literature [15,39].
A2) The appropriate benzoic acid (3,4-dimethoxybenzoic acid
(4) or 3,4,5-trimethoxybenzoic acid (5), 1mmol) was dissolved in
dichloromethane (15mL) and POCl3 (1mmol) was added at room
temperature. After 30min, the reactional mixture was cooled (ice
bath) and 8-aminooctan-1-ol or 10-aminodecan-1-ol (1.2mmol)
and DIPEA (4mmol) were added. The reaction was stirred for
1e2 h at room temperature. The purification conditions are
described in literature [15].
N-(6-Hydroxyhexyl)benzamide (6). Procedure A1. h¼ 81%. 1H
NMR (CDCl3): d¼ 1.40e1.42 (4H, m, N(CH2)2(CH2)2), 1.54e1.66 (4H,
m, NCH2CH2(CH2)2CH2), 1.77 (1H, s, OH), 3.42e3.47 (2H, m, NCH2),
3.63 (2H, t, J¼ 6.5 Hz, CH2O), 6.28 (1H, s, NH), 7.39e7.43 (2H, m,
H(3) and H(5)), 7.46e7.50 (1H, m, H(4)), 7.74e7.77 (2H, m, H(2) and
H(6)). 13C NMR (CDCl3): d¼ 25.4 (N(CH2)3CH2), 26.7 (N(CH2)2CH2),
29.8 (NCH2CH2), 32.7 (N(CH2)4CH2), 40.0 (NCH2), 62.8 (CH2O), 127.0
(C(2) and C(6)), 128.7 (C(3) and C(5)), 131.5 (C(4)), 134.9 (C(1)), 167.8
(CO). ESI/MS m/z (%): 222 (MþþH, 100), 204 (41).
N-(6-Hydroxyhexyl)-3-methoxybenzamide (7). Procedure A1.
h¼ 88%. 1H NMR (CDCl3): d¼ 1.32e1.38 (4H, m, N(CH2)2(CH2)2),
1.48e1.62 (4H, m, NCH2CH2(CH2)2CH2), 2.85 (1H, s, OH), 3.36e3.41
(2H,m, NCH2), 3.58 (2H, t, J¼ 6.5 Hz, CH2O), 3.79 (3H, s, OCH3), 6.89
(1H, t, J¼ 5.4 Hz, NH), 6.99 (1H, ddd, J¼ 1.4, 2.4, 7.7 Hz, H(4)), 7.27
(1H, dd, J¼ 7.6, 7.7 Hz, H(5)), 7.31 (1H, ddd, J¼ 1.4, 1.6, 7.6 Hz, H(6)),
7.36 (1H, dd, J¼ 1.6, 2.4 Hz, H(2)). 13C NMR (CDCl3): d¼ 25.3
(N(CH2)3CH2), 26.6 (N(CH2)2CH2), 29.5 (NCH2CH2), 32.5
(N(CH2)4CH2), 40.0 (NCH2), 55.4 (OCH3), 62.4 (CH2O), 112.5 (C(4)),
117.4 (C(6)),118.9 (C(2)),129.5 (C(5)),136.2 (C(1)),159.7 (C(3)), 167.7
(CO). ESI/MS m/z (%): 274 (MþþNa, 53), 252 (MþþH, 18), 135 (100).
N-(6-Hydroxyhexyl)-4-methoxybenzamide (8). Procedure A1.
h¼ 69%. 1H NMR (CDCl3): d¼ 1.36e1.46 (4H, m, N(CH2)2(CH2)2),
1.52e1.65 (4H, m, NCH2CH2(CH2)2CH2), 1.76 (1H, s, OH), 3.38e3.49
(2H,m, NCH2), 3.63 (2H, t, J¼ 6.4 Hz, CH2O), 3.83 (3H, s, OCH3), 6.16
(1H, s, NH), 6.82e6.99 (2H, m, H(3) and H(5)), 7.66e7.81 (2H, m,
H(2) and H(6)). 13C NMR (CDCl3): d¼ 25.4 (N(CH2)3CH2), 26.7
(N(CH2)2CH2), 29.9 (NCH2CH2), 32.7 (N(CH2)4CH2), 39.9 (NCH2),
55.5 (OCH3), 62.8 (CH2O), 113.9 (C(3) and C(5)), 127.2 (C(1)), 128.8
(C(2) and C(6)), 162.2 (C(4)), 167.3 (CO). ESI/MS m/z (%): 274
(MþþNa, 48), 252 (MþþH, 14), 135 (100).
N-(6-Hydroxyhexyl)-3,4-dimethoxybenzamide (9) and N-(6-
Hydroxyhexyl)-3,4,5-trimethoxybenzamide (12). Procedure A1.
Structural analysis described in literature [39].
N-(8-Hydroxyoctyl)-3,4-dimethoxybenzamide (10). Proced-
ure A2. Structural analysis described in literature [15].
N-(10-Hydroxydecyl)-3,4-dimethoxybenzamide (11), N-(8-
Hydroxyoctyl)-3,4,5-trimethoxybenzamide (13) and N-(10-
Hydroxydecyl)-3,4,5-trimethoxybenzamide (14). Procedure A2.
Structural analysis described in literature [15].
4.1.1.2. General procedure to obtain aldehyde derivatives (15e23).
Pyridinium chlorochromate (1.5mmol) and dichloromethane
(20mL) were added and kept under stirring for 5e7min. Benzoic
acid amide derivative (6e14) was added and stirred for 2 h.
Thereafter diethyl ether (15mL) was added and the solid was fil-
trated using a Celite pad. The solvent was evaporated and the
compound purified by silica gel flash chromatography using ethyl
acetate as eluting system. The control reaction was performed by
TLC (silica gel, ethyl acetate). The procedure was adapted from the
literature [40].
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d¼ 1.28e1.40 (2H, m, N(CH2)2CH2), 1.51e1.66 (4H, m,
NCH2CH2CH2CH2), 2.39 (2H, td, J¼ 1.7, 7.2 Hz, CH2CHO), 3.31e3.42
(2H, m, NCH2), 6.74 (1H, s, NH), 7.30e7.38 (2H, m, H(3) and H(5)),
7.38e7.46 (1H,m, H(4)), 7.64e7.88 (2H,m, H(2) and H(6)), 9.69 (1H,
t, J¼ 1.7 Hz, CHO). 13C NMR (CDCl3): d¼ 21.6 (N(CH2)2CH2), 26.4
(N(CH2)3CH2), 29.3 (NCH2CH2), 39.8 (NCH2), 43.7 (CH2CHO), 127.0
(C(2) and C(6)), 128.5 (C(3) and C(5)), 131.4 (C(4)), 134.6 (C(1)), 167.8
(CONH), 202.7 (CHO). ESI/MS m/z (%): 220 (MþþH, 7), 105 (100).
3-Methoxy-N-(6-oxohexyl)benzamide (16). h¼ 56%. 1H NMR
(CDCl3): d¼ 1.28e1.38 (2H, m, N(CH2)2CH2), 1.51e1.64 (4H, m,
NCH2CH2CH2CH2), 2.38 (2H, td, J¼ 1.6, 7.2 Hz, CH2CHO), 3.33e3.41
(2H, m, NCH2), 3.76 (3H, s, OCH3), 6.83 (1H, s, NH), 6.96 (1H, ddd,
J¼ 1.4, 2.6, 7.7 Hz, H(4)), 7.24 (1H, dd, J¼ 7.6, 7.7 Hz, H(5)), 7.28 (1H,
ddd, J¼ 1.4, 1.6, 7.6 Hz, H(6)), 7.33 (1H, dd, J¼ 1.6, 2.3 Hz, H(2)), 9.69
(1H, t, J¼ 1.6 Hz, CHO). 13C NMR (CDCl3): d¼ 21.5 (N(CH2)2CH2),
26.3 (N(CH2)3CH2), 29.3 (NCH2CH2), 39.7 (NCH2), 43.6 (CH2CHO),
55.3 (OCH3),112.3 (C(4)), 117.4 (C(6)),118.8 (C(2)),129.4 (C(5)),136.1
(C(1)), 159.7 (C(3)), 167.5 (CONH), 202.7 (CHO). ESI/MSm/z (%): 250
(MþþH, 35), 135 (100).
4-Methoxy-N-(6-oxohexyl)benzamide (17). h¼ 43%. 1H NMR
(CDCl3): d¼ 1.35e1.45 (2H, m, N(CH2)2CH2), 1.57e1.70 (4H, m,
NCH2CH2CH2CH2), 2.45 (2H, td, J¼ 1.6, 7.2 Hz, CH2CHO), 3.35e3.48
(2H,m, NCH2), 3.83 (3H, s, OCH3), 6.19 (1H, s, NH), 6.82e6.99 (2H,m,
H(3) and H(5)), 7.66e7.81 (2H, m, H(2) and H(6)), 9.76 (1H, t,
J¼ 1.6 Hz, CHO). 13C NMR (CDCl3): d¼ 21.7 (N(CH2)2CH2), 26.5
(N(CH2)3CH2), 29.6 (NCH2CH2), 39.8 (NCH2), 43.8 (CH2CHO), 55.5
(OCH3), 113.8 (C(3) and C(5)), 127.1 (C(1)), 128.8 (C(2) and C(6)),
162.2 (C(4)), 167.2 (CONH), 202.6 (CHO). ESI/MS m/z (%): 250
(MþþH, 12), 135 (100).
3,4-Dimethoxy-N-(6-oxohexyl)benzamide (18). h¼ 45%. 1H
NMR (CDCl3): d¼ 1.34e1.46 (2H,m, N(CH2)2CH2), 1.54e1.73 (4H,m,
NCH2CH2CH2CH2), 2.44 (2H, td, J¼ 1.6, 7.2 Hz, CH2CHO), 3.38e3.48
(2H, m, NCH2), 3.90 (6H, s, 2OCH3), 6.29 (1H, s, NH), 6.83 (1H, d,
J¼ 8.4 Hz, H(5)), 7.27 (1H, dd, J¼ 2.0, 8.4 Hz, H(6)), 7.41 (1H, d,
J¼ 2.0 Hz, H(2)), 9.75 (1H, t, J¼ 1.6 Hz, CHO). 13C NMR (CDCl3):
d¼ 21.6 (N(CH2)2CH2), 26.5 (N(CH2)3CH2), 29.5 (NCH2CH2), 39.8
(NCH2), 43.8 (CH2CHO), 56.1 (2OCH3), 110.4 (C(5)), 110.7 (C(2)),
119.3 (C(6)), 127.5 (C(1)), 149.1 (C(3)), 151.8 (C(4)), 167.2 (CONH),
202.6 (CHO). EI/MS m/z (%): 279 (Mþ, 41), 251 (87), 250 (26), 236
(72), 222 (28), 195 (58), 194 (40), 182 (22), 181 (90), 166 (82), 165
(100), 137 (32), 122 (26), 92 (20), 79 (35), 77 (42).
3,4-Dimethoxy-N-(8-oxooctyl)benzamide (19). h¼ 66%. 1H
NMR (CDCl3): d¼ 1.22e1.44 (6H, m, N(CH2)2(CH2)3), 1.54e1.68 (4H,
m, NCH2CH2(CH2)3CH2), 2.41 (2H, td, J¼ 1.8, 7.3 Hz, CH2CHO),
3.34e3.46 (2H, m, NCH2), 3.90 (6H, s, 2OCH3), 6.17 (1H, s, NH),
6.84 (1H, d, J¼ 8.4 Hz, H(5)), 7.25 (1H, dd, J¼ 2.0, 8.4 Hz, H(6)), 7.41
(1H, d, J¼ 2.0 Hz, H(2)), 9.75 (1H, t, J¼ 1.8 Hz, CHO). 13C NMR
(CDCl3): d¼ 22.0 (N(CH2)2CH2), 26.9 (N(CH2)5CH2), 29.1
(N(CH2)3(CH2)2), 29.8 (NCH2CH2), 40.1 (NCH2), 43.9 (CH2CHO), 56.1
(2OCH3), 110.4 (C(5)), 110.8 (C(2)), 119.2 (C(6)), 127.6 (C(1)), 149.1
(C(3)), 151.7 (C(4)), 167.2 (CONH), 202.9 (CHO). ESI/MS m/z (%): 308
(MþþH, 100), 165 (60), 124 (23).
3,4-Dimethoxy-N-(10-oxodecyl)benzamide (20). h¼ 71%. 1H
NMR (CDCl3): d¼ 1.23e1.37 (10H,m, N(CH2)2(CH2)5), 1.51e1.64 (4H,
m, NCH2CH2(CH2)5CH2), 2.40 (2H, td, J¼ 1.8, 7.3 Hz, CH2CHO),
3.37e3.44 (2H, m, NCH2), 3.90 (6H, s, 2OCH3), 6.20 (1H, s, NH),
6.83 (1H, d, J¼ 8.4 Hz, H(5)), 7.25 (1H, dd, J¼ 2.0, 8.4 Hz, H(6)), 7.41
(1H, d, J¼ 2.0 Hz, H(2)), 9.74 (1H, t, J¼ 1.8 Hz, CHO). 13C NMR
(CDCl3): d¼ 22.1 (N(CH2)2CH2), 27.0 (N(CH2)7CH2), 29.2
(N(CH2)3CH2), 29.3 (N(CH2)6CH2), 29.4 (N(CH2)4(CH2)2), 29.8
(NCH2CH2), 40.2 (NCH2), 44.0 (CH2CHO), 56.1 (2OCH3), 110.4
(C(5)), 110.8 (C(2)), 119.2 (C(6)), 127.6 (C(1)), 149.1 (C(3)), 151.7
(C(4)), 167.2 (CONH), 203.0 (CHO).
3,4,5-Trimethoxy-N-(6-oxohexyl)benzamide (21). h¼ 50%. 1HNMR (CDCl3): d¼ 1.35e1.45 (2H, m, N(CH2)2CH2), 1.57e1.72 (4H, m,
NCH2CH2CH2CH2), 2.46 (2H, td, J¼ 1.6, 7.1 Hz, CH2CHO), 3.41e3,49
(2H,m, NCH2), 3.86 (3H, s, OCH3), 3.88 (6H, s, 2OCH3), 6.32 (1H, s,
NH), 7.00 (2H, s, H(2) and H(6)), 9.76 (1H, t, J¼ 1.6 Hz, CHO). 13C
NMR (CDCl3): d¼ 21.5 (N(CH2)2CH2), 26.4 (N(CH2)3CH2), 29.4
(NCH2CH2), 39.9 (NCH2), 43.8 (CH2CHO), 56.4 (2OCH3), 61.0
(OCH3), 104.5 (C(2) and C(6)), 130.2 (C(1)), 141.0 (C(4)), 153.3 (C(3)
and C(5)), 167.4 (CONH), 202.6 (CHO). EI/MS m/z (%): 309 (Mþ, 92),
281 (35), 280 (21), 266 (59), 225 (37), 224 (27), 211 (89), 196 (96),
195 (100), 154 (20), 152 (29), 137 (26), 109 (20), 81 (25).
3,4,5-Trimethoxy-N-(8-oxooctyl)benzamide (22). h¼ 63%. 1H
NMR (CDCl3): d¼ 1.27e1.45 (6H, m, N(CH2)2(CH2)3), 1.54e1.71 (4H,
m, NCH2CH2(CH2)3CH2), 2.43 (2H, t, J¼ 6.8 Hz, CH2CHO), 3.36e3.48
(2H,m, NCH2), 3.87 (3H, s, OCH3), 3.90 (6H, s, 2OCH3), 6.08 (1H, s,
CONH), 6.98 (2H, s, H(2) and H(6)), 9.76 (1H, s, CHO). 13C NMR
(CDCl3): d¼ 22.0 (N(CH2)2CH2), 26.9 (N(CH2)5CH2), 29.1
(N(CH2)3(CH2)2), 29.8 (NCH2CH2), 40.3 (NCH2), 44.0 (CH2CHO), 56.5
(2OCH3), 61.0 (OCH3), 104.5 (C(2) and C(6)), 130.5 (C(1)), 141.0
(C(4)), 153.3 (C(3) and C(5)), 167.4 (CONH), 202.9 (CHO). ESI/MSm/z
(%): 360 (MþþNa, 20), 338 (MþþH,100),195 (88),169 (24), 154 (78).
3,4,5-Trimethoxy-N-(10-oxodecyl)benzamide (23). h¼ 77%.
1H NMR (CDCl3): d¼ 1.23e1.43 (10H, m, N(CH2)2(CH2)5), 1.52e1.71
(4H, m, NCH2CH2(CH2)5CH2), 2.46 (2H, t, J¼ 7.2 Hz, CH2CHO),
3.38e3.47 (2H, m, NCH2), 3.87 (3H, s, OCH3), 3.90 (6H, s, 2OCH3),
6.09 (1H, s, NH), 6.98 (2H, s, H(2) and H(6)), 9.75 (1H, s, CHO). 13C
NMR (CDCl3): d¼ 22.2 (N(CH2)2CH2), 27.1 (N(CH2)7CH2), 29.2
(N(CH2)3CH2), 29.3 (N(CH2)6CH2), 29.4 (N(CH2)4(CH2)2), 29.9
(NCH2CH2), 40.4 (NCH2), 44.0 (CH2CHO), 56.5 (2OCH3), 61.0
(OCH3), 104.5 (C(2) and C(6)), 130.5 (C(1)), 141.0 (C(4)), 153.3 (C(3)
and C(5)), 167.3 (CONH), 203.0 (CHO). ESI/MS m/z (%): 366 (MþþH,
100), 195 (33), 154 (35).
4.1.1.3. General procedure to obtain nitrone derivatives (24e42).
In a microwave vial the aldehyde derivative (15e23, 1 mmol), hy-
droxylamine hydrochloride (N-tert-butyl, N-benzyl or N-cyclo-
hexyl, 1.5mmol) and NaHCO3 (1.5mmol) were added in 3e5mL of
tetrahydrofuran at 90 C for 10min with 10 s of pre-stirring.
Dichloromethane (20mL) was added and extracted with water
(2 10mL). The organic phases were combined, the solvent was
evaporated and the compound purified by silica gel flash chroma-
tography using ethyl acetate:methanol (9:1) as eluting system. The
control reaction was performed by TLC (silica gel, ethyl acetate).
a-5-Benzamidopentyl-N-tert-butyl nitrone (24). h¼ 51%. 1H
NMR (CD3OD): d¼ 1.38e1.53 (11H, m, C(CH3)3 and N(CH2)3CH2),
1.57e1.73 (4H, m, N(CH2)2CH2CH2CH2), 2.39e2.58 (2H, m,
NCH2CH2), 3.40 (2H, t, J¼ 7.0, NCH2), 7.25 (1H, t, J¼ 5.7 Hz, CH]
Nþ), 7.41e7.48 (2H, m, H(3) and H(5)), 7.49e7.55 (1H, m, H(4)),
7.77e7.85 (2H, m, H(2) and H(6)). 13C NMR (CD3OD): d¼ 26.1
(N(CH2)2CH2), 27.9 (N(CH2)3CH2), 28.0 (C(CH3)3), 28.2 (NCH2CH2),
30.1 (N(CH2)4CH2), 40.7 (NCH2), 70.5 (C(CH3)3), 128.2 (C(2) and
C(6)), 129.5 (C(3) and C(5)), 132.5 (C(4)), 135.8 (C(1)), 142.2 (CH]
Nþ), 170.2 (CO). ESI/MS m/z (%): 313 (MþþNa, 26), 291 (MþþH, 7),
290 (Mþ, 5), 105 (100). ESI/HRMS calcd for C17H26N2O2 (Mþ):
290.1994, found 290.1966.
a-5-Benzamidopentyl-N-benzyl nitrone (25). h¼ 31%. 1H
NMR (CD3OD): d¼ 1.38e1.53 (2H, m, N(CH2)3CH2), 1.57e1.72 (4H,
m, N(CH2)2CH2CH2CH2), 2.44e2.53 (2H, m, NCH2CH2), 3.38 (2H, t,
J¼ 7.0 Hz, NCH2), 4.93 (2H, s, NþCH2), 7.31e7.48 (8H, m, H(20e60),
H(3) and H(5) and CH]Nþ), 7.49e7.56 (1H,m, H(4)), 7.78e7.84 (2H,
m, H(2) and H(6)). 13C NMR (CD3OD): d¼ 26.0 (N(CH2)2CH2), 27.8
(N(CH2)3(CH2)2), 30.1 (NCH2CH2), 40.7 (NCH2), 69.4 (NþCH2), 128.2
(C(2) and C(6)), 129.5 (C(3) and C(5)), 129.8 (C(20) and C(60)), 130.0
(C(40)), 130.1 (C(30) and C(50)), 132.6 (C(4)), 134.7 (C(10)), 135.9
(C(1)), 146.3 (CH]Nþ), 170.2 (CO). ESI/MSm/z (%): 348 (MþþNaþH,
22), 347 (MþþNa, 87), 325 (MþþH, 100), 105 (60), 91 (22). ESI/
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a-5-Benzamidopentyl-N-cyclohexyl nitrone (26). h¼ 58%. 1H
NMR (CD3OD): d¼ 1.20e1.94 (16H, m, N(CH2)2(CH2)3 and
NþCH(CH2)5), 2.41e2.52 (2H, m, NCH2CH2), 3.39 (2H, t, J¼ 7.0 Hz,
NCH2), 3.74e3.86 (1H, m, NþCH), 7.21 (1H, t, J¼ 5.9 Hz, CH]Nþ),
7.41e7.48 (2H,m, H(3) and H(5)), 7.49e7.56 (1H,m, H(4)), 7.76e7.85
(2H, m, H(2) and H(6)). 13C NMR (CD3OD): d¼ 25.9
(NþCHCH2CH2CH2CH2), 26.1 (NþCH(CH2)2CH2 and N(CH2)2CH2),
27.5 (N(CH2)3CH2), 27.7 (NCH2CH2), 30.1 (N(CH2)4CH2), 31.9
(NþCHCH2(CH2)3CH2), 40.7 (NCH2), 74.5 (NþCH), 128.2 (C(2) and
C(6)), 129.5 (C(3) and C(5)), 132.5 (C(4)), 135.9 (C(1)), 144.2 (CH]
Nþ), 170.2 (CO). ESI/MSm/z (%): 339 (MþþNa, 94), 317 (MþþH,100).
ESI/HRMS calcd for C19H29N2O2 (MþþH): 317.2224, found 317.2222.
a-5-(3-Methoxybenzamido)pentyl-N-tert-butyl nitrone (27).
h¼ 83%. 1H NMR (CD3OD): d¼ 1.43e1.49 (11H, m, C(CH3)3 and
N(CH2)3CH2), 1.58e1.71 (4H, m, N(CH2)2CH2CH2CH2), 2.45e2.52
(2H, m, NCH2CH2), 3.39 (2H, t, J¼ 7.0 Hz, NCH2), 3.84 (3H, s, OCH3),
7.06e7.10 (1H, m, H(2)), 7.25 (1H, t, J¼ 5.7 Hz, CH]Nþ), 7.32e7.40
(3H, m, H(4e6)). 13C NMR (CD3OD): d¼ 26.1 (N(CH2)2CH2), 27.9
(N(CH2)3CH2), 28.0 (C(CH3)3), 28.2 (NCH2CH2), 30.1 (N(CH2)4CH2),
40.7 (NCH2), 55.9 (OCH3), 70.5 (C(CH3)3), 113.6 (C(4)), 118.3 (C(6)),
120.3 (C(2)), 130.6 (C(5)), 137.2 (C(1)), 142.2 (CH]Nþ), 161.3 (C(3)),
170.0 (CO). ESI/MS m/z (%): 321 (MþþH, 8), 135 (100). ESI/HRMS
calcd for C19H29N2O3 (MþþH): 321.2173, found 321.2163.
a-5-(3-Methoxybenzamido)pentyl-N-benzyl nitrone (28).
h¼ 38%. 1H NMR (CD3OD): d¼ 1.39e1.49 (2H, m, N(CH2)3CH2),
1.56e1.69 (4H, m, N(CH2)2CH2CH2CH2), 2.43e2.52 (2H, m,
NCH2CH2), 3.37 (2H, t, J¼ 7.0 Hz, NCH2), 3.83 (3H, s, OCH3), 4.92 (2H,
s, NþCH2), 7.05e7.10 (1H, m, H(2)), 7.31e7.45 (9H, m, H(20e60),
H(4e6) and CH]Nþ). 13C NMR (100MHz, CD3OD): d¼ 26.0
(N(CH2)2CH2), 27.7 (N(CH2)3CH2), 27.8 (N(CH2)4CH2), 30.1
(NCH2CH2), 40.7 (NCH2), 55.9 (OCH3), 69.4 (NþCH2), 113.6 (C(4)),
118.3 (C(6)), 120.3 (C(2)), 129.8 (C(20) and C(60)), 129.9 (C(40)), 130.1
(C(30) and C(50)), 130.6 (C(5)), 134.7 (C(10)), 137.2 (C(1)), 146.2 (CH]
Nþ), 161.3 (C(3)), 170.0 (CO). ESI/MS m/z (%): 377 (MþþNa, 58), 355
(MþþH, 100), 135 (84), 91 (25). ESI/HRMS calcd for C21H27N2O3
(MþþH): 355.2016, found 355.2046.
a-5-(3-Methoxybenzamido)pentyl-N-cyclohexyl nitrone
(29). h¼ 78%. 1H NMR (CD3OD): d¼ 1.20e1.93 (16H, m,
N(CH2)2(CH2)3 and NþCH(CH2)5), 2.42e2.52 (2H,m, NCH2CH2), 3.39
(2H, t, J¼ 7.0 Hz, NCH2), 3.74e3.83 (1H, m, NþCH), 3.84 (3H, s,
OCH3), 7.06e7.10 (1H, m, H(2)), 7.20 (1H, t, J¼ 5.9 Hz, CH]Nþ),
7.32e7.40 (3H, m, H(4e6)). 13C NMR (CD3OD): d¼ 25.9
(NþCHCH2CH2CH2CH2), 26.1 (NþCH(CH2)2CH2 and N(CH2)2CH2),
27.5 (N(CH2)3CH2), 27.7 (NCH2CH2), 30.1 (N(CH2)4CH2), 31.9
(NþCHCH2(CH2)3CH2), 40.7 (NCH2), 55.9 (OCH3), 74.6 (NþCH), 113.7
(C(4)), 118.3 (C(6)), 120.3 (C(2)), 130.6 (C(5)), 137.2 (C(1)), 144.2
(CH]Nþ), 161.3 (C(3)), 170.0 (CO). ESI/MS m/z (%): 369 (MþþNa,
62), 347 (MþþH, 48), 135 (100). ESI/HRMS calcd for C20H31N2O3
(MþþH): 347.2329, found 347.2324.
a-5-(4-Methoxybenzamido)pentyl-N-tert-butyl nitrone (30).
h¼ 62%. 1H NMR (CD3OD): d¼ 1.39e1.51 (11H, m, C(CH3)3 and
N(CH2)3CH2), 1.56e1.71 (4H, m, N(CH2)2CH2CH2CH2), 2.42e2.53
(2H, m, NCH2CH2), 3.38 (2H, t, J¼ 7.0 Hz, NCH2), 3.84 (3H, s, OCH3),
6.93e7.01 (2H, m, H(3) and H(5)), 7.25 (1H, t, J¼ 5.7 Hz, CH]Nþ),
7.76e7.81 (2H, m, H(2) and H(6)). 13C NMR (CD3OD): d¼ 26.1
(N(CH2)2CH2), 27.9 (N(CH2)3CH2), 28.0 (C(CH3)3), 28.2 (NCH2CH2),
30.2 (N(CH2)4CH2), 40.6 (NCH2), 55.9 (OCH3), 70.5 (C(CH3)3), 114.7
(C(3) and C(5)), 127.9 (C(1)), 130.1 (C(2) and C(6)), 142.2 (CH]Nþ),
163.8 (C(4)), 169.8 (CO). ESI/MS m/z (%): 343 (MþþNa, 16), 321
(MþþH, 4), 135 (100). ESI/HRMS calcd for C18H29N2O3 (MþþH):
321.2173, found 321.2172.
a-5-(4-Methoxybenzamido)pentyl-N-benzyl nitrone (31).
h¼ 31%. 1H NMR (CD3OD): d¼ 1.37e1.49 (2H, m, N(CH2)3CH2),
1.56e1.69 (4H, m, N(CH2)2CH2CH2CH2), 2.43e2.53 (2H, m,NCH2CH2), 3.36 (2H, t, J¼ 7.0 Hz, NCH2), 3.83 (3H, s, OCH3), 4.93
(2H, s, NþCH2), 6.92e7.03 (2H, m, H(3) and H(5)), 7.30e7.46 (6H, m,
H(20e60) and CH]Nþ), 7.73e7.83 (2H, m, H(2) and H(6)). 13C NMR
(CD3OD): d¼ 26.0 (N(CH2)2CH2), 27.8 (N(CH2)3(CH2)2), 30.2
(NCH2CH2), 40.6 (NCH2), 55.9 (OCH3), 69.4 (NþCH2), 114.7 (C(3) and
C(5)), 127.9 (C(1)), 129.8 (C(20) and C(60)), 129.9 (C(40)), 130.1 (C(2),
C(6), C(30) and C(50)), 134.7 (C(10)), 146.2 (CH]Nþ), 163.9 (C(4)),
169.8 (CO). ESI/MSm/z (%): 378 (MþþNaþH, 24), 377 (MþþNa,100),
286 (26), 228 (32). ESI/HRMS calcd for C21H26N2O3Na (MþþNa):
377.1836, found 377.1840.
a-5-(4-Methoxybenzamido)pentyl-N-cyclohexyl nitrone
(32). h¼ 39%. 1H NMR (CD3OD): d¼ 1.19e1.92 (16H, m,
N(CH2)2(CH2)3 and NþCH(CH2)5), 2.41e2.51 (2H,m, NCH2CH2), 3.37
(2H, t, J¼ 7.0 Hz, NCH2), 3.74e3.83 (1H, m, NþCH), 3.84 (3H, s,
OCH3), 6.93e7.00 (2H, m, H(3) and H(5)), 7.20 (1H, t, J¼ 5.9 Hz,
CH]Nþ), 7.75e7.82 (2H, m, H(2) and H(6)). 13C NMR (CD3OD):
d¼ 25.9 (NþCHCH2CH2CH2CH2), 26.1 (NþCH(CH2)2CH2 and
N(CH2)2CH2), 27.5 (N(CH2)3CH2), 27.7 (NCH2CH2), 30.2
(N(CH2)4CH2), 31.9 (NþCHCH2(CH2)3CH2), 40.6 (NCH2), 55.9 (OCH3),
74.5 (NþCH), 114.7 (C(3) and C(5)), 127.9 (C(1)), 130.1 (C(2) and
C(6)), 144.2 (CH]Nþ), 163.8 (C(4)), 169.8 (CO). ESI/MS m/z (%): 369
(MþþNa, 17), 135 (100). ESI/HRMS calcd for C20H30N2O3Na
(MþþNa): 369.2149, found 369.2146.
a-5-(3,4-Dimethoxybenzamido)pentyl-N-tert-butyl nitrone
(33). h¼ 90%. 1H NMR (CD3OD): d¼ 1.40e1.49 (11H,m, C(CH3)3 and
N(CH2)3CH2), 1.58e1.71 (4H, m, N(CH2)2CH2CH2CH2), 2.43e2.52
(2H, m, NCH2CH2), 3.38 (2H, t, J¼ 7.0 Hz, NCH2), 3.88 (6H, s,
2OCH3), 7.00 (1H, d, J¼ 8.4 Hz, H(5)), 7.25 (1H, t, J¼ 5.7 Hz, CH]
Nþ), 7.42e7.49 (2H, m, H(2) and H(6)). 13C NMR (CD3OD): d¼ 26.1
(N(CH2)2CH2), 27.9 (N(CH2)3CH2), 28.0 (C(CH3)3), 28.2 (NCH2CH2),
30.2 (N(CH2)4CH2), 40.7 (NCH2), 56.5 (2OCH3), 70.5 (C(CH3)3),
112.0 (C(5) and C(2)), 121.8 (C(6)), 128.2 (C(1)), 142.2 (CH]Nþ),
150.3 (C(3)), 153.4 (C(4)), 169.7 (CO). ESI/MS m/z (%): 373 (MþþNa,
16), 373 (MþþH, 8), 165 (100). ESI/HRMS calcd for C19H31N2O4
(MþþH): 351.2278, found 351.2260.
a-5-(3,4-Dimethoxybenzamido)pentyl-N-benzyl nitrone
(34). h¼ 43%. 1H NMR (CD3OD): d¼ 1.39e1.49 (2H,m, N(CH2)3CH2),
1.55e1.69 (4H, m, N(CH2)2CH2CH2CH2), 2.43e2.53 (2H, m,
NCH2CH2), 3.37 (2H, t, J¼ 7.0 Hz, NCH2), 3.87 (6H, s, 2OCH3), 4.93
(2H, s, NþCH2), 7.00 (1H, d, J¼ 8.2 Hz, H(5)), 7.31e7.48 (8H, m,
H(20e60), CH]Nþ, H(2) and H(6)). 13C NMR (CD3OD): d¼ 26.0
(N(CH2)2CH2), 27.8 (N(CH2)3(CH2)2), 30.2 (NCH2CH2), 40.7 (NCH2),
56.5 (2OCH3), 69.4 (NþCH2), 112.0 (C(5) and C(2)), 121.8 (C(6)),
128.2 (C(1)), 129.8 (C(20) and C(60)), 129.9 (C(40)), 130.1 (C(30) and
C(50)), 134.7 (C(10)), 146.2 (CH]Nþ), 150.3 (C(3)), 153.4 (C(4)), 169.7
(CO). ESI/MSm/z (%): 407 (MþþNa, 28), 385 (MþþH, 95), 165 (100).
ESI/HRMS calcd for C22H29N2O4 (MþþH): 385.2122, found 385.2121.
a-5-(3,4-Dimethoxybenzamido)pentyl-N-cyclohexyl nitrone
(35). h¼ 57%. 1H NMR (CD3OD): d¼ 1.19e1.91 (16H, m,
N(CH2)2(CH2)3 and NþCH(CH2)5), 2.40e2.59 (2H,m, NCH2CH2), 3.38
(2H, t, J¼ 7.0 Hz, NCH2), 3.72e3.84 (1H, m, NþCH), 3.88 (6H, s,
2OCH3), 7.00 (1H, d, J¼ 8.3 Hz, H(5)), 7.19 (1H, t, J¼ 5.7 Hz, CH]
Nþ), 7.40e7.49 (2H, m, H(2) and H(6)). 13C NMR (CD3OD): d¼ 25.9
(NþCHCH2CH2CH2CH2), 26.1 (NþCH(CH2)2CH2 and N(CH2)2CH2),
27.5 (N(CH2)3CH2), 27.7 (NCH2CH2), 30.2 (N(CH2)4CH2), 31.9
(NþCHCH2(CH2)3CH2), 40.7 (NCH2), 56.5 (2OCH3), 74.6 (NþCH),
112.0 (C(5) and C(2)), 121.8 (C(6)), 128.2 (C(1)), 144.2 (CH]Nþ),
150.3 (C(3)), 153.4 (C(4)), 169.7 (CO). ESI/MS m/z (%): 399 (MþþNa,
40), 377 (MþþH, 24), 165 (100). ESI/HRMS calcd for C21H33N2O4
(MþþH): 377.2435, found 377.2426.
a-7-(3,4-Dimethoxybenzamido)heptyl-N-tert-butyl nitrone
(36). h¼ 71%. 1H NMR (CD3OD): d¼ 1.37e1.43 (6H, m,
N(CH2)2(CH2)2CH2CH2), 1.47 (9H, s, C(CH3)3), 1.53e1.65 (4H, m,
N(CH2)4CH2CH2CH2), 2.40e2.49 (2H, m, NCH2CH2), 3.36 (2H, t,
J¼ 7.2 Hz, NCH2), 3.87 (6H, s, 2OCH3), 7.00 (1H, d, J¼ 8.5 Hz,
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H(6)). 13C NMR (CD3OD): d¼ 26.3 (N(CH2)2CH2), 27.9 (N(CH2)5CH2),
28.0 (C(CH3)3), 28.3 (N(CH2)3CH2), 30.1 (N(CH2)4CH2), 30.5
(NCH2CH2), 30.6 (N(CH2)6CH2), 41.0 (NCH2), 56.5 (2OCH3), 70.5
(C(CH3)3), 112.0 (C(5) and C(2)), 121.7 (C(6)), 128.2 (C(1)), 142.4
(CH]Nþ), 150.2 (C(3)), 153.4 (C(4)), 169.7 (CO). ESI/MSm/z (%): 401
(MþþNa, 3), 379 (MþþH,1), 308 (58), 165 (100), 124 (28). ESI/HRMS
calcd for C21H35N2O4 (MþþH): 379.2591, found 379.2577.
a-9-(3,4-Dimethoxybenzamido)nonyl-N-tert-butyl nitrone
(37). h¼ 82%. 1H NMR (CD3OD): d¼ 1.31e1.42 (10H, m,
N(CH2)2(CH2)4CH2CH2), 1.47 (9H, s, C(CH3)3), 1.53e1.64 (4H, m,
N(CH2)6CH2CH2CH2), 2.40e2.49 (2H, m, NCH2CH2), 3.35 (2H, t,
J¼ 7.2 Hz, NCH2), 3.87 (6H, s, 2OCH3), 7.00 (1H, d, J¼ 8.6 Hz,
H(5)), 7.24 (1H, t, J¼ 5.7 Hz, CH]Nþ), 7.41e7.47 (2H, m, H(2) and
H(6)). 13C NMR (CD3OD): d¼ 26.4 (N(CH2)2CH2), 28.0 (C(CH3)3),
28.1 (N(CH2)7CH2), 28.3 (N(CH2)3CH2), 30.3 (N(CH2)6CH2), 30.4
(N(CH2)4CH2), 30.5 (N(CH2)5CH2), 30.6 (NCH2CH2(CH2)6CH2), 41.0
(NCH2), 56.5 (2OCH3), 70.5 (C(CH3)3), 111.9 (C(5)), 112.0 (C(2)),
121.7 (C(6)), 128.3 (C(1)), 142.4 (CH]Nþ), 150.2 (C(3)), 153.4 (C(4)),
169.7 (CO). ESI/MSm/z (%): 406 (MþþNa, 3), 165 (100), 139 (27), 124
(47). ESI/HRMS calcd for C23H38N2O4Na (MþþNa): 429.2724, found
429.2716.
a-5-(3,4,5-Trimethoxybenzamido)pentyl-N-tert-butyl
nitrone (38). h¼ 94%. 1H NMR (CD3OD): d¼ 1.40e1.50 (11H, m,
C(CH3)3 and N(CH2)3CH2), 1.59e1.71 (4H, m, N(CH2)2CH2CH2CH2),
2.44e2.52 (2H,m, NCH2CH2), 3.39 (2H, t, J¼ 7.0 Hz, NCH2), 3.80 (3H,
s, OCH3), 3.89 (6H, s, 2OCH3), 7.17 (2H, s, H(2) and H(6)), 7.25 (1H,
t, J¼ 5.7 Hz, CH]Nþ). 13C NMR (CD3OD): d¼ 26.1 (N(CH2)2CH2),
27.9 (N(CH2)3CH2), 28.0 (C(CH3)3), 28.2 (NCH2CH2), 30.2
(N(CH2)4CH2), 40.8 (NCH2), 56.7 (2OCH3), 61.1 (OCH3), 70.5
(C(CH3)3), 106.0 (C(2) and C(6)), 131.1 (C(1)), 142.1 (C(4)), 142.2
(CH]Nþ), 154.4 (C(3) and C(5)), 169.5 (CO). EI/MSm/z (%): 380 (Mþ,
37), 307 (20), 266 (31), 212 (45), 196 (51), 195 (100), 96 (34).
a-5-(3,4,5-Trimethoxybenzamido)pentyl-N-benzyl nitrone
(39). h¼ 41%. 1H NMR (CD3OD): d¼ 1.39e1.48 (2H,m, N(CH2)3CH2),
1.58e1.69 (4H, m, N(CH2)2CH2CH2CH2), 2.45e2.53 (2H, m,
NCH2CH2), 3.37 (2H, t, J¼ 7.0 Hz, NCH2), 3.80 (3H, s, OCH3), 3.88 (6H,
s, 2OCH3), 4.92 (2H, s, NþCH2), 7.17 (2H, s, H(2) and H(6)),
7.32e7.44 (6H, m, H(20e60) and CH]Nþ). 13C NMR (CD3OD):
d¼ 26.0 (N(CH2)2CH2), 27.7 (N(CH2)3CH2), 27.8 (N(CH2)4CH2), 30.1
(NCH2CH2), 40.8 (NCH2), 56.7 (2OCH3), 61.1 (OCH3), 69.4
(NþCH2), 106.0 (C(2) and C(6)), 129.8 (C(20) and C(60)), 129.9 (C(40)),
130.1 (C(30) and C(50)), 131.1 (C(1)), 134.7 (C(10)), 142.1 (C(4)), 146.2
(CH]Nþ),154.4 (C(3) and C(5)), 169.5 (CO). ESI/MS m/z (%): 415
(MþþH, 100). ESI/HRMS calcd for C23H31N2O5 (MþþH): 415.2227,
found 415.2229.
a-5-(3,4,5-Trimethoxybenzamido)pentyl-N-cyclohexyl
nitrone (40). h¼ 69%. 1H NMR (CD3OD): d¼ 1.22e1.91 (16H, m,
N(CH2)2(CH2)3 and NþCH(CH2)5), 2.44e2.51 (2H,m, NCH2CH2), 3.39
(2H, t, J¼ 7.0 Hz, NCH2), 3.74e3.79 (1H, m, NþCH), 3.80 (3H, s,
OCH3), 3.89 (6H, s, 2OCH3), 7.17 (2H, s, H(2) and H(6)), 7.20 (1H, t,
J¼ 5.9 Hz, CH]Nþ). 13C NMR (CD3OD): d¼ 25.9
(NþCHCH2CH2CH2CH2), 26.1 (NþCH(CH2)2CH2 and N(CH2)2CH2),
27.5 (N(CH2)3CH2), 27.8 (NCH2CH2), 30.1 (N(CH2)4CH2), 31.9
(NþCHCH2(CH2)3CH2), 40.8 (NCH2), 56.7 (2OCH3), 61.1 (OCH3),
74.6 (NþCH), 106.0 (C(2) and C(6)), 131.1 (C(1)), 142.1 (C(4)), 144.2
(CH]Nþ), 154.5 (C(3) and C(5)), 169.5 (CO). ESI/MS m/z (%): 407
(MþþH, 8), 195 (100). ESI/HRMS calcd for C22H35N2O5 (MþþH):
407.2540, found 407.2534.
a-7-(3,4,5-Trimethoxybenzamido)heptyl-N-tert-butyl
nitrone (41). h¼ 82%. 1H NMR (CD3OD): d¼ 1.35e1.44 (6H, m,
N(CH2)2(CH2)2CH2CH2), 1.47 (9H, s, C(CH3)3), 1.53e1.66 (4H, m,
N(CH2)4CH2CH2CH2), 2.42e2.49 (2H, m, NCH2CH2), 3.37 (2H, t,
J¼ 7.3 Hz, NCH2), 3.80 (3H, s, OCH3), 3.89 (6H, s, 2OCH3), 7.16 (1H,
s, H(2) and H(6)), 7.24 (1H, t, J¼ 5.7 Hz, CH]Nþ). 13C NMR (CD3OD):d¼ 26.3 (N(CH2)2CH2), 27.9 (N(CH2)5CH2), 28.0 (C(CH3)3), 28.3
(N(CH2)3CH2), 30.1 (N(CH2)4CH2), 30.5 (NCH2CH2), 30.6
(N(CH2)6CH2), 41.1 (NCH2), 56.7 (2OCH3), 61.1 (OCH3), 70.5
(C(CH3)3), 105.9 (C(2) and C(6)), 131.2 (C(1)), 142.0 (C(4)), 142.3
(CH]Nþ), 154.4 (C(3) and C(5)), 169.5 (CO). ESI/MS m/z (%): 431
(MþþNa, 3), 400 (37), 195 (83), 154 (100). ESI/HRMS calcd for
C22H36N2O5Na (MþþNa): 431.2516, found 431.2505.
a-9-(3,4,5-Trimethoxybenzamido)nonyl-N-tert-butyl nitrone
(42). h¼ 69%. 1H NMR (CD3OD): d¼ 1.31e1.43 (10H, m,
N(CH2)2(CH2)4CH2CH2), 1.47 (9H, s, C(CH3)3), 1.52e1.65 (4H, m,
N(CH2)6CH2CH2CH2), 2.41e2.48 (2H, m, NCH2CH2), 3.36 (2H, t,
J¼ 7.2 Hz, NCH2), 3.80 (3H, s, OCH3), 3.89 (6H, s, 2OCH3), 7.16 (2H,
s, H(2) and H(6)), 7.24 (1H, t, J¼ 5.7 Hz, CH]Nþ). 13C NMR (CD3OD):
d¼ 26.4 (N(CH2)2CH2), 28.0 (C(CH3)3), 28.1 (N(CH2)7CH2), 28.3
(N(CH2)3CH2), 30.3 (N(CH2)6CH2), 30.4 (N(CH2)4CH2), 30.5
(NCH2CH2(CH2)3CH2), 30.6 (N(CH2)8CH2), 41.2 (NCH2), 56.7
(2OCH3), 61.1 (OCH3), 70.5 (C(CH3)3), 105.9 (C(2) and C(6)), 131.2
(C(1)), 142.0 (C(4)), 142.4 (CH]Nþ), 154.4 (C(3) and C(5)), 169.4
(CO). ESI/MSm/z (%): 459 (MþþNa, 3), 437 (MþþH, 2), 428 (26), 195
(87), 154 (100). ESI/HRMS calcd for C24H41N2O5 (MþþH): 437.3010,
found 437.3004.
4.2. Pharmacology
4.2.1. Evaluation of acetyl and butyrylcholinesterase inhibitory
activity
The inhibitory activity of compounds under study on AChE and
BChE was evaluated following the Ellman's method [15] (see SI).
4.2.2. Evaluation of AChE kinetics and AChE-inhibitor kinetics
To determine the steady-state kinetic parameters (Km, Michaelis
constant and Vmax, maximum rate) of AChE, their enzymatic ac-
tivities were evaluated in the presence of different ATCI concen-
trations (see SI). To evaluate the mechanism of AChE inhibition of
the most promising compounds (33 and 38) substrate-dependent
kinetic experiments were also performed (see SI).
4.2.3. Evaluation of cytotoxicity/antioxidant outline in cell-based
assays
4.2.3.1. Cell lines and culture conditions. SH-SY5Y cells (ATCC,
Manassas, VA, USA), a human neuroblastoma cell line [41,42], and
HepG2 (ECACC, UK), a human hepatocellular carcinoma cell line
were used (see SI).
4.2.3.2. Cytotoxicity screening and cell viability assays.
Differentiated SH-SY5Y and HepG2 cells were exposed to increased
concentrations of the test compounds (1, 10 and 50 mM) in cell
culture medium for 24 h or 48 h, respectively. The cytotoxic end-
points (MTT and reasazurin reduction assays) are described in
literature [38,43] and in SI.
4.2.3.3. Cellular antioxidant screening. The nitrones’ antioxidant
differentiated efficiency in the presence of an oxidative stressor
was evaluated using SH-SY5Y cells treated with nitrones 33 and
38 at different concentrations (10, 50 and 100 mM). Cellular oxida-
tive damage was induced by the incubation of different OS-induced
agents, namely hydrogen peroxide (H2O2 1mM for 4 h), tert-butyl
hydroperoxide (t-BHP 200 mM for 4 h); rotenone and antimycin A
(ROT/AA 1 mM for 4 h); and doxorubicin (DOX 1 mM for 4 h). Two
protocols have been used: a) the tested compounds were pre-
incubated for 24 h and then pro-oxidant agents were added to
the cell culture; and b) the pro-oxidant agents were first added to
the cell culture and then the tested compounds were incubated for
24 h. After incubation time, cellular metabolic activity was deter-
mined using the resazurin reduction assay [43].
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Data analysis for all the studies are specified in SI.4.4. Molecular modelling studies
4.4.1. Ligands conformational analysis
Nitrone compounds 27e35, 38e40, and Donepezil enantiomers
3D structures were built and optimised using the Maestro GUI [44].
All molecules were submitted to 5000 steps of Monte Carlo
conformational search as implemented in MacroModel [45]. Con-
formers were generated by randomly moving rotatable bonds and
resulting geometries were optimised using 2500 iteration of the
Polack Ribiere Conjugate Gradient algorithm and energy evaluated
by means of the OPLS3 force field [46]. Water environment effects
were mimicked according to GB/SA implicit solvation model. The
global minimum of each molecule was submitted to docking
simulations.4.4.2. Docking simulation studies
Target models of AChE and BChE were designed starting from
Protein Data Bank (PDB) [47] crystallographic structures 4EY7 [48]
and 1P0I [49], respectively. The original PDB entries were selected
taking into account the organism of provenience (Homo sapiens),
the best available X-ray resolution and, in the case of 4EY7, the co-
crystallised ligand (Donepezil). In order to add hydrogen atoms and
missing residues, and to remove water molecules, before being
used in docking simulation both target models were submitted to
the Protein Preparation Wizard [50]. According to Glide docking
software [51e54] the binding site was defined by means of a
27,000 Å3 large regular box centred onto the catalytic Ser residue
203 and 198 for hAChE and hBChE models, respectively. Flexible
ligand docking algorithm at extra precision level (XP) was adopted
for exploring the recognition properties of compounds 27e35 and
38e40. The binding free energy was estimated by the MM-GBSA
method. Solvent effects were mimicked by the VSGB 2.0 contin-
uum dielectric model [55], as implemented in Prime [56].4.4.3. Pan Assay INterference compoundS (PAINS) evaluation
FAF4-Drug [57,58] and ZINC PAINS Pattern Identifier [59] web
services were used to theoretically explore the PAINS properties of
the chemical structures of the investigated compounds. Both
methods did not highlight any issue related to the molecules under
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